Delivery Order 36F79719D0108-36C24924N0192
Award Date 11/13/23
Potential Completion Date 12/13/23
Potential Value $60K
Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy used to treat Fabry disease in veterans. This firm fixed-price delivery order, awarded on March 4, 2026, with an ultimate completion date of March 6, 2026, represents a child order under the parent Pharmaceuticals and Drugs Federal Supply...
- The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of publicly traded biopharmaceutical company Amicus Therapeutics, Inc. The order, valued at $21,089.47, is for the specialty medication Galafold (migalastat) to treat Fabry disease. The delivery order was placed against Amicus Therapeutics US, LLC's five-year Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), a...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $18,520.05 delivery order to Amicus Therapeutics US, LLC under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for GALAFOLD specialty medication migalastat 123 mg to treat Fabry disease and will be fulfilled by Amicus Therapeutics, Inc., the parent company of Amicus Therapeutics US, LLC, with place of performance in Cranbury, New Jersey. The...
- The Department of Veterans Affairs, Veterans Integrated Service Network 21, awarded a delivery order to Amicus Therapeutics US, LLC on February 10, 2026, for emergency pharmacy supply of Migalastat 123 mg capsules (Galafold), an FDA-approved enzyme replacement therapy for treating Fabry disease in veterans. This firm fixed-price delivery order, valued at $22,839.61 with a completion date of April 11, 2026, carries no set-aside designation and will be performed at a VA facility in Philadelphia,...
- The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., for the specialty medication Galafold (migalastat) to treat Fabry disease. The $21,089.47 award was placed against Amicus Therapeutics, Inc.'s Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract with the General Services Administration, which provides a mechanism for federal agencies to procure...
- This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The order, valued at $21,089.47, is for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The order is a firm fixed-price contract with no set-aside designation. Amicus Therapeutics US, LLC holds a Pharmaceuticals and Drugs Federal Supply Schedule contract...
- Amicus Therapeutics US, LLC has been awarded a delivery order valued at $21,891.21 by Veterans Integrated Service Network 5 (VISN 5) for the supply of Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. This firm fixed-price delivery order, awarded on August 28, 2025, is a child contract under the parent Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule held by the Department of Veterans Affairs. The contract will be performed in Philadelphia, Pennsylvania,...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on February 8, 2026, with an ultimate completion date of February 10, 2026, represents a continuation of the vendor's extensive supply relationship with the VA. The...
- The Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Migalastat (Galafold 123 mg), an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on March 13, 2026, with an ultimate completion date of April 13, 2026, represents one of over 150 task orders placed under Amicus Therapeutics' parent Federal...
- The Department of Veterans Affairs Veterans Health Administration awarded a $60,374.73 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Amicus Therapeutics US, LLC. The firm fixed price order is for the emergency provision of Galafold to the Philadelphia VA Medical Center and runs from August 23, 2023 through September 15, 2023. Amicus Therapeutics, Inc., the parent company of Amicus Therapeutics US, LLC, will provide the enzyme replacement therapy drug to...